| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.22 | 2e-09 |
| mRNA | N9-isopropylolomoucine | CTRPv2 | pan-cancer | AAC | 0.19 | 5e-06 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.18 | 1e-05 |
| mRNA | TGX221 | GDSC1000 | pan-cancer | AAC | -0.19 | 0.0002 |
| mRNA | Bosutinib | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0005 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0006 |
| mRNA | BRD-K07442505 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0006 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0009 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.14 | 0.001 |
| mRNA | AM-580 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.001 |